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All-trans retinoic acid (ATRA), a carboxylic acid form of
vitamin A, was a revolutionary discovery in the treatment of
acute promyelocytic leukemia (APL) that was found largely
by chance in late 80s. The molecular hallmark of APL is the
presence of a balanced reciprocal translocation resulting in
the PML/RAR-a gene fusion, which represents the target of
ATRA therapy. ATRA is considered to be a safe drug. Pseu-
dotumor cerebri (PTC) is a rare neurological adverse event of
ATRA that was mainly reported in pediatric population. It is
characterized by neurologic and ocular signs and symptoms
of increased intracranial pressure in the absence of any
intracranial pathology or secondary causes of intracranial
hypertension.
Herein we report four cases of young female patients who
were diagnosed with APL and experienced PTC with ATRA
treatment. In three cases ﬂuconazolewas taken concurrently.
Symptoms completely subsided with the temporary with-
drawal of ATRA and discontinuation of ﬂuconazole. PTC
symptoms did not recur after reintroducing ATRA.
In conclusion, we report a case series of young female pa-
tients that is suggestive of young age, female gender and
concurrent use of ﬂuconazole to be associatedwith increased
risk of developing PTC with ATRA treatment. Fluconazole
should not be used concurrently with ATRA. We also con-
clude that the drug could be safely reintroduced once the
symptoms had resolved.239
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Background: T-cell prolymphocytic leukemia (T-PLL) is a
rare neoplasm with an aggressive course and a median
survival of < 1 year. Outcomes have improved since the
advent of alemtuzumab but the duration of response re-
mains short. Hematopoietic stem cell transplantation (HSCT)
is thought to offer long term disease control; however the
feasibility of this approach is not well deﬁned.
Aims: To determine the transplant referral pattern and
outcomes from a large center and to ascertain the survival of
patients (pts) treated with alemtuzumab based regimens.
Methods: Following IRB approval, all pts diagnosed with
T-PLL from 1997-2014 at Mayo Clinic Rochester were iden-
tiﬁed. T-PLL diagnosis was established based on the 2008WHO criteria. Survival was estimated using the Kaplan-
Meier method with log ranks to compare curves.
Results: 41 pts with T-PLL were identiﬁed; 23 (56%) were
males, with a median age at diagnosis of 66 years (range, 32-
85). Median follow up was 18 months (0.4-66.1). At last
follow up, 32 pts (78%) have died. Lymphadenopathy was
present in 68%, hepato-splenomegaly in 61% and cutaneous
inﬁltration in 10%. Median HBwas 13.5 gm/dl (6.6-17.3), WBC
26.25 x 109/L (9.4-551), ALC 17.1 x 109/L (5.7-540) and Plt 164
x 109/L (5-299). Among evaluable pts, FISH analysis was
positive for 14q32 in 27/28, trisomy 8 in 4/10, 11q22 deletion
in 4/6 and 17p deletion in 2/3. Next generation sequencing in
two pts revealed ATM R3008H with JAK3M511I mutations in
one and ATM loss in the other. Twenty (49%) pts received
alemtuzumab based therapy, 13 as intravenous, 4 as subcu-
taneous injection and 3 unknown. Fourteen (34%) received
non-alemtuzumab based therapies, 2 pts received best sup-
portive care, while 4 (10%) have not required treatment to
date. Median survival for pts receiving alemtuzumab based
therapy was 29.5 vs 10.3 months for all other therapies (P
0.0011). Median survival between intravenous vs subcu-
taneous alemtuzumab administration was 40.5 vs 10.9
months (P 0.0011). Thirteen pts were > 70 years of age and
not considered for HSCT. Among the eligible cohort, 22 (85%)
were unable to proceed due to progressive disease (20), lack
of donor (1) or failed autologousmobilization (1). Only 15% of
the eligible pts received HSCT; 3 underwent myeloablative
allogeneic HSCT, while one patient underwent an autologous
HSCT. Median survival post-transplant was 4 months (2.5-
32). All three allogeneic recipients died from graft versus
host disease while the autologous recipient died within 4
months post-transplant from disease progression.
Conclusion: Alemtuzumab based regimens are associated
with improved survival outcome in pts with T-PLL. Although
transplant is thought to be the best consolidation approach, a
striking minority were eligible for such therapy mainly due
to progressive disease. Recurring JAK3 mutations and ATM
deletions reported by us and others should be exploited for
future clinical trials.240
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Background: CD33 is expressed on the surface of myelo-
blasts in w90% of AML, representing a promising, clinically
validated target. SGNeCD33A is an anti-CD33 engineered
cysteine antibody conjugated to w2 molecules of a pyrrolo-
benzodiazepine (PBD) dimer, a highly potent DNA cross-
linking agent. Upon binding, SGNeCD33A is internalized and
transported to the lysosomes where PBD dimer is released
through proteolytic cleavage of the linker, crosslinking DNA
and leading to cell death.
Methods: A phase 1 dose-escalation study (NCT01902329)
evaluating the safety and anti-leukemic activity of SGN-
CD33A is ongoing. AML patients (ECOG 0-1) must have
relapsed disease after initial remission (CR) of > 3 months or
declined induction/consolidation. SGN-CD33A is given IV
q3wk up to 4 cycles and optional maintenance for patients
